Emi1 Is Required for Normal Cell Cycle Progression in Zebrafish Myelopoiesis and Likely Functions as a Haploinsufficient Tumor Suppressor on Chromosome 6q in Human Leukmias.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1405-1405
Author(s):  
Jennifer Rhodes ◽  
Adam Amsterdam ◽  
Karen Ho ◽  
Stefan Heinrichs ◽  
John P. Kanki ◽  
...  

Abstract Myelopoiesis is a developmental process through which stem cells give rise to mature monocytes and granulocytes by means of a tightly regulated cellular program. The molecular mechanisms controlling myelopoiesis are incompletely understood, as are the abnormalities in this process that give rise to myeloid cell diseases, such as leukemia, myelodysplasia, and myeloproliferative syndromes. These diseases are commonly associated with somatically acquired large chromosomal deletions, making the identification of the causative tumor suppressor genes difficult. To learn more about the genes required for normal myelopoiesis, which we postulated might be mutated during the molecular pathogenesis of myeloid malignancies, we performed a screen using a panel of insertional mutants provided by Nancy Hopkins (MIT) to identify zebrafish lines with deficiencies in myeloperoxidase (mpo), a gene specifically expressed in granulocytes. As part of this screen, we identified the line hi2648, in which homozygous mutants have a severe reduction in the numbers of mature myeloid cells expressing either mpo or l-plastin, and in which the small numbers of residual myeloid cells are abnormally large. We bred hi2648 mutant fish to a line carrying the pu.1:GFP transgene and found that the homozygous mutant embryos displayed decreased numbers but relatively large GFP-positive cells, which were also observed in cytospins of FACS-purified, GFP-expressing cells, consistent with our in situ analysis. Hi2648 harbors a retroviral insertion that disrupts the gene emi1 between exons one and two, resulting in decreased levels of emi1 RNA assayed by whole- mount in situ analysis. We confirmed that the hematopoietic phenotype in this line is due to disruption of emi1 by showing that we could phenocopy the mutant using emi1-specific morpholinos and also by rescuing the mutant phenotype using forced expression of emi1 RNA. The Emi1 gene product has been shown to inhibit anaphase-promoting complex during interphase of the cell cycle. We analyzed emi1-mutant embryos for cell cycle defects by FACS analysis of propidium-iodide stained cells at 21 hpf, and showed that impaired emi1 expression results in an accumulation of cells in G2 phase, presumably due to premature activation of APC during S- and G2-phase with an inability to accumulate adequate levels cyclin B. We also observed a range of increased of levels of cellular DNA content greater than the normal 4n complement, suggesting that loss of emi1 also promotes abortive endoreduplication. Mutational analysis indicated gene-specific disruption in of emi1 in a human leukemia cell line, suggesting that this gene represents one of the long-sought haploinsufficient tumor suppressors located on the long arm of human chromosome 6 (del 6q), whose loss promotes genomic instability during leukemogenesis and the progression of MDS to AML in man.

Planta Medica ◽  
2019 ◽  
Vol 86 (01) ◽  
pp. 55-60 ◽  
Author(s):  
Leice M. R. de Novais ◽  
Luiz F. Ferreira ◽  
Paulo T. de Sousa ◽  
Tereza A. N. Ribeiro ◽  
Marcos J. Jacinto ◽  
...  

AbstractChemical investigation of the stems of Dulacia egleri resulted in the isolation of eglerisine (1), a compound with a rare sesquiterpenoid tropolone skeleton. Its structure was determined by analysis of spectrometric and spectroscopic data, including HRESIMS, 1D, and 2D NMR. The antiproliferative effects of eglerisine were tested in human leukemia lineages. In the Kasumi-1 lineage, an acute myeloid leukemia cell line, eglerisine reduced cell metabolism, as determined by the resazurin assay. Eglerisine did not induce cell death by either apoptotic or necrotic mechanisms. However, a reduction of the absolute number of cells was observed. Eglerisine induced cell cycle arrest after 72 h of treatment by phosphorylation of H2AX histone, reducing the S phase and increasing the G2 phase of the cell cycle.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4203-4203
Author(s):  
Nobuyoshi Kosaka ◽  
Yusuke Yamamoto ◽  
Nami Nogawa ◽  
Keiichi Sugiura ◽  
Hiroshi Miyazaki ◽  
...  

Abstract Mature microRNA (miRNA) originated from primary miRNA (pri-miRNA) is a new group of potential regulator for cell differentiation, apoptosis, proliferation and oncogenesis. Some miRNAs were recently identified in hematopoietic cells, while the roles of miRNAs in erythrocytic and megakaryocytic cells had not been well examined. As a first step to explore for miRNAs specific for hematopoietic lineage, the expressions of several known primary microRNAs in erythrocytic and megakaryocytic cell lines, such as TF-1, HL-60, HEK293 and UT-7 leukemia cells, were examined by RT-PCR. We consequently focused on the pri-miR-10a, a primary transcript of miR-10a located within Hox gene clusters, and found the significant expression in TF-1 cells and UT-7/EPO cells. The UT-7/EPO cells were a subline established from the original UT-7 cells, as well as UT-7/GM and UT-7/TPO cells; therefore it was suitable for the further comparative analysis. Interestingly, in UT-7/EPO cells, the expression of pri-miR-10a increased under stimulation of erythropoietin (EPO; 1U/mL and 10U/mL). Based on these observations, it was postulated that pri-miR-10a might involve in modulating erythrocyte differentiation or proliferation. To clarify the role of pri-miR-10a in UT-7/EPO, we have established clonal cell lines by transfecting UT-7/EPO cells with either the control vector or the pri-miR-10a expression vector pCMV-pri-miR10a. Overexpression of pri-miR-10a in the UT-7/EPO cell line (miR10a-UT-7/EPO) was confirmed by RT-PCR. MiR10a-UT-7/EPO showed higher proliferation rate even at low concentration of EPO (0.1 mU/mL). Overexpression of pri-miR-10a did not appear to affect HOXB4 and HOXA1 expression, as similar mRNA levels were seen in both cell lines. It was notable that the cellular size of miR10a-UT-7/EPO became larger than its parental cells. Morphological studies of miR10a-UT-7/EPO were performed in detail. It is possible that miR-10a was capable to modulate morphological features particularly in cellular size relating to cell cycle regulation. For instance, loss of the E2F family members result in marked macrocytic anemia with megaloblastic features in adult mice (Mol Cell. 2000 Aug;6(2):281–91., Mol Cell Biol. 2003 May;23(10):3607–22., Blood. 2006 Aug 1;108(3):886–95.). Data presented here hypothesized that the roles of miR-10a in erythroid cells are tightly associated with cell cycle.


2005 ◽  
Vol 25 (5) ◽  
pp. 1645-1654 ◽  
Author(s):  
Katie L. Kathrein ◽  
Rachelle Lorenz ◽  
Angela Minniti Innes ◽  
Erin Griffiths ◽  
Susan Winandy

ABSTRACT Ikaros is a hematopoietic cell-specific zinc finger DNA binding protein that plays an important role in lymphocyte development. Genetic disruption of Ikaros results in T-cell transformation. Ikaros null mice develop leukemia with 100% penetrance. It has been hypothesized that Ikaros controls gene expression through its association with chromatin remodeling complexes. The development of leukemia in Ikaros null mice suggests that Ikaros has the characteristics of a tumor suppressor gene. In this report, we show that the introduction of Ikaros into an established mouse Ikaros null T leukemia cell line leads to growth arrest at the G0/G1 stage of the cell cycle. This arrest is associated with up-regulation of the cell cycle-dependent kinase inhibitor p27kip1, the induction of expression of T-cell differentiation markers, and a global and specific increase in histone H3 acetylation status. These studies provide strong evidence that Ikaros possesses the properties of a bona fide tumor suppressor gene for the T-cell lineage and offer insight into the mechanism of Ikaros's tumor suppressive activity.


1988 ◽  
Vol 6 (3) ◽  
pp. 209-220 ◽  
Author(s):  
Hiroyuki Tsuda ◽  
Mamoru Sakaguchi ◽  
Makoto Kawakita ◽  
Shimpei Nakazawa ◽  
Taijiro Mori ◽  
...  

2005 ◽  
Vol 52 (4) ◽  
pp. 889-896 ◽  
Author(s):  
Martina Rezácová ◽  
Jirina Vávrová ◽  
Doris Vokurková ◽  
Ales Tichý ◽  
Jirí Knízek ◽  
...  

In this work we studied the relationship between the enhanced expression of DR5 receptor and the effect of combination of TRAIL and ionizing radiation on cell cycle arrest and apoptosis induction in human leukemia cell line HL-60. DR5, APO2.7 and cell cycle were analyzed by flow cytometry. Proteins Bid and Mcl-1 were analyzed by Western-blotting. For clonogenic survival, colony assay on methylcellulose was used. Ionizing radiation caused significantly enhanced positivity of DR5 receptors 24 h after irradiation with high doses (6 and 8 Gy). An increase of DR5 receptor positivity after a dose of 2 Gy was not statistically significant and application of TRAIL 48 h after irradiation did not increase the apoptosis induction. However, a decrease of radiation-induced G(2) phase arrest and an increase of apoptosis were observed when TRAIL was applied 16 h before irradiation with the dose of 2 Gy. Incubation with 6 microg/l TRAIL for 16 h reduced D(0) value from 2.9 Gy to 1.5 Gy. The induction of apoptosis by TRAIL was accompanied by Bid cleavage and a decrease of antiapoptotic Mcl-1 16 h after incubation with TRAIL. TRAIL in concentration of 6 microg/l applied 16 h before irradiation by the dose of 1.5 Gy caused the death of 63% of clonogenic tumor cells, similarly as the dose of 2.9 Gy alone, which is in good correlation with the enhanced apoptosis induction.


Blood ◽  
1998 ◽  
Vol 92 (2) ◽  
pp. 462-471 ◽  
Author(s):  
Keita Kirito ◽  
Mie Uchida ◽  
Masaaki Takatoku ◽  
Koichi Nakajima ◽  
Toshio Hirano ◽  
...  

We recently determined that erythropoietin (EPO) activates 3 members of the signal transducer and activator of transcription (STAT) family, Stat1α, Stat3, and Stat5, in the human EPO-dependent cell lines, UT-7 and UT-7/EPO (Kirito et al, J Biol Chem 272:16507, 1997). In addition, we have shown that Stat1α, but not Stat3, is involved in EPO-induced cellular proliferation. In this study, we examined the roles of Stat1α and Stat3 in EPO-induced erythroid differentiation. UT-7/GM was used as a model system, because this cell line can differentiate into erythroid-lineage cells with EPO treatment (Komatsu et al, Blood 89:4021, 1997). We found that EPO did not activate Stat1α or Stat3 in UT-7/GM cells. Transfection experiments showed that both Stat1α and Stat3 inhibited the induction by EPO of γ-globin and erythroid-specific 5-aminolevulinate synthetase transcripts, resulting in a reduction of the percentage of hemoglobin-positive cells. Dominant negative forms of Stat1α or Stat3 promoted the EPO-induced erythroid differentiation of UT-7/GM cells, even in the presence of granulocyte-macrophage colony-stimulating factor, although this cytokine never induced erythroid differentiation of the parent UT-7/GM cells with or without EPO. A cell cycle analysis showed that the constitutive activation of Stat1α, but not Stat3, shortened the period of G0/G1 prolongation caused by EPO stimulation. Taken together, our data suggest that Stat1α and Stat3 act as negative regulators in EPO-induced erythroid differentiation. Specifically, Stat1α may activate a cell cycle-associated gene(s), leading to the entry of cells into the cell cycle.


Sign in / Sign up

Export Citation Format

Share Document